Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Stages
2.3.2 Market Size By Age Group
2.3.3 Market Size By Diagnosis And Treatment
2.3.4 Market Size By Route Of Administration
2.3.5 Market Size By End User
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Pricing Analysis & Forecast
4.1.1 Overview
4.1.2 Average Treatment Cost per Patient by Therapy Type
4.1.3 Price Benchmarking by Key Players
4.1.4 Regional Cost Differences and Affordability Metrics
4.1.5 Emerging Pricing Models
4.2 Regulatory & Reimbursement Landscape
4.2.1 Overview
4.2.2 FDA, EMA, and Regional Regulatory Approvals for Dry AMD Therapies
4.2.3 Percentage of Therapies with Orphan Drug Designation
4.2.4 Reimbursement Coverage Statistics by Region and Therapy Type
4.2.5 Upcoming Regulatory Changes Impacting Market Access
4.3 Disease Epidemiology & Patient Metrics
4.3.1 Overview
4.3.2 Prevalence and Incidence Rates by Age Group and Region
4.3.3 Patient Demographics (Gender, Ethnicity, Comorbidity Trends)
4.3.4 Rate of Disease Progression Among Diagnosed Patients
4.3.5 Patient Awareness and Diagnosis Rates (%)
4.4 Clinical & Treatment Adoption Metrics
4.4.1 Overview
4.4.2 Adoption Rate of Different Therapy Types
4.4.3 Average Time from Diagnosis to Treatment Initiation
4.4.4 Compliance & Adherence Rates (%)
4.4.5 Physician Preference Trends for Therapy Selection
4.5 Research & Development Insights
4.5.1 Overview
4.5.2 Number of Therapies in Clinical Trials (Phase I, II, III)
4.5.3 Annual R&D Investment in Dry AMD Therapies
4.5.4 Patent Filings and Technological Innovations
4.5.5 Emerging Novel Therapeutics Pipeline Analysis
4.6 Healthcare Infrastructure & Service Metrics
4.6.1 Overview
4.6.2 Number of Specialized Eye Clinics and Centers Offering Dry AMD Care
4.6.3 Diagnostic Device Penetration Rates (OCT, Fundus Imaging)
4.6.4 Average Patient Visits and Follow-Up Frequencies
4.6.5 Telemedicine Adoption for Dry AMD Management
5. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast, By Stages, 2021 – 2032, Value (Usd Billion)
5.1 Introduction
5.2 Early Age-Related Macular Degeneration
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Intermediate Age-Related Macular Degeneration
5.4 Late Age-Related Macular Degeneration
6. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast, By Age Group, 2021 – 2032, Value (Usd Billion)
6.1 Introduction
6.2 Above 40 Years
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Above 60 Years
6.4 Above 75 Years
7. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast, By Diagnosis And Treatment, 2021 – 2032, Value (Usd Billion)
7.1 Introduction
7.2 Treatment
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Diagnosis
8. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast, By Route Of Administration, 2021 – 2032, Value (Usd Billion)
8.1 Introduction
8.2 Oral
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Injectables
9. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast, By End User, 2021 – 2032, Value (Usd Billion)
9.1 Introduction
9.2 Hospital & Clinics
9.2.1 Key Trends
9.2.2 Market Size & Forecast, 2021 – 2032
9.3 Diagnostic Centers
9.4 Academic Research Institutes
9.5 Others
10. Dry Age-Related Macular Degeneration Market Segmental Analysis & Forecast By Region, 2021 – 2032, Value (Usd Billion)
10.1 Introduction
10.2 North America
10.2.1 Key Trends
10.2.2 Dry Age-Related Macular Degeneration Market Size & Forecast, By Stages, 2021 – 2032
10.2.3 Dry Age-Related Macular Degeneration Market Size & Forecast, By Age Group, 2021 – 2032
10.2.4 Dry Age-Related Macular Degeneration Market Size & Forecast, By Diagnosis And Treatment, 2021 – 2032
10.2.5 Dry Age-Related Macular Degeneration Market Size & Forecast, By Route Of Administration, 2021 – 2032
10.2.6 Dry Age-Related Macular Degeneration Market Size & Forecast, By End User, 2021 – 2032
10.2.7 Dry Age-Related Macular Degeneration Market Size & Forecast, By Country, 2021 – 2032
10.2.7.1 USA
10.2.7.2 Canada
10.3 Europe
10.3.1 Key Trends
10.3.2 Dry Age-Related Macular Degeneration Market Size & Forecast, By Stages, 2021 – 2032
10.3.3 Dry Age-Related Macular Degeneration Market Size & Forecast, By Age Group, 2021 – 2032
10.3.4 Dry Age-Related Macular Degeneration Market Size & Forecast, By Diagnosis And Treatment, 2021 – 2032
10.3.5 Dry Age-Related Macular Degeneration Market Size & Forecast, By Route Of Administration, 2021 – 2032
10.3.6 Dry Age-Related Macular Degeneration Market Size & Forecast, By End User, 2021 – 2032
10.3.7 Dry Age-Related Macular Degeneration Market Size & Forecast, By Country, 2021 – 2032
10.3.7.1 Germany
10.3.7.2 UK
10.3.7.3 France
10.3.7.4 Italy
10.3.7.5 Spain
10.3.7.6 Russia
10.3.7.7 Poland
10.3.7.8 Rest of Europe
10.4 Asia-Pacific
10.4.1 Key Trends
10.4.2 Dry Age-Related Macular Degeneration Market Size & Forecast, By Stages, 2021 – 2032
10.4.3 Dry Age-Related Macular Degeneration Market Size & Forecast, By Age Group, 2021 – 2032
10.4.4 Dry Age-Related Macular Degeneration Market Size & Forecast, By Diagnosis And Treatment, 2021 – 2032
10.4.5 Dry Age-Related Macular Degeneration Market Size & Forecast, By Route Of Administration, 2021 – 2032
10.4.6 Dry Age-Related Macular Degeneration Market Size & Forecast, By End User, 2021 – 2032
10.4.7 Dry Age-Related Macular Degeneration Market Size & Forecast, By Country, 2021 – 2032
10.4.7.1 China
10.4.7.2 India
10.4.7.3 Japan
10.4.7.4 South Korea
10.4.7.5 Australia
10.4.7.6 ASEAN Countries
10.4.7.7 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Key Trends
10.5.2 Dry Age-Related Macular Degeneration Market Size & Forecast, By Stages, 2021 – 2032
10.5.3 Dry Age-Related Macular Degeneration Market Size & Forecast, By Age Group, 2021 – 2032
10.5.4 Dry Age-Related Macular Degeneration Market Size & Forecast, By Diagnosis And Treatment, 2021 – 2032
10.5.5 Dry Age-Related Macular Degeneration Market Size & Forecast, By Route Of Administration, 2021 – 2032
10.5.6 Dry Age-Related Macular Degeneration Market Size & Forecast, By End User, 2021 – 2032
10.5.7 Dry Age-Related Macular Degeneration Market Size & Forecast, By Country, 2021 – 2032
10.5.7.1 Brazil
10.5.7.2 Argentina
10.5.7.3 Mexico
10.5.7.4 Colombia
10.5.7.5 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Key Trends
10.6.2 Dry Age-Related Macular Degeneration Market Size & Forecast, By Stages, 2021 – 2032
10.6.3 Dry Age-Related Macular Degeneration Market Size & Forecast, By Age Group, 2021 – 2032
10.6.4 Dry Age-Related Macular Degeneration Market Size & Forecast, By Diagnosis And Treatment, 2021 – 2032
10.6.5 Dry Age-Related Macular Degeneration Market Size & Forecast, By Route Of Administration, 2021 – 2032
10.6.6 Dry Age-Related Macular Degeneration Market Size & Forecast, By End User, 2021 – 2032
10.6.7 Dry Age-Related Macular Degeneration Market Size & Forecast, By Country, 2021 – 2032
10.6.7.1 UAE
10.6.7.2 Saudi Arabia
10.6.7.3 Qatar
10.6.7.4 Egypt
10.6.7.5 South Africa
10.6.7.6 Rest of Middle East & Africa
11. Competitive Landscape
11.1 Key Players' Positioning
11.2 Competitive Developments
11.2.1 Key Strategies Adopted (%), By Key Players, 2024
11.2.2 Year-Wise Strategies & Development, 2021 – 2025
11.2.3 Number Of Strategies Adopted By Key Players, 2024
11.3 Market Share Analysis, 2024
11.4 Product/Service & Application Benchmarking
11.4.1 Product/Service Specifications & Features By Key Players
11.4.2 Product/Service Heatmap By Key Players
11.4.3 Application Heatmap By Key Players
11.5 Industry Start-Up & Innovation Landscape
11.6 Key Company Profiles
11.6 Key Company Profiles
11.6.1 Bayer AG
11.6.1.1 Company Overview & Snapshot
11.6.1.2 Product/Service Portfolio
11.6.1.3 Key Company Financials
11.6.1.4 SWOT Analysis
11.6.2 Pfizer Inc.
11.6.3 Amgen Inc.
11.6.4 Biogen
11.6.5 Novartis AG
11.6.6 F. Hoffmann-La Roche Ltd
11.6.7 Samsung Bioepis
11.6.8 Bausch Health Companies Inc.
11.6.9 Regeneron Pharmaceuticals Inc.
11.6.10 Santen Pharmaceuticals Inc.
11.6.11 Allergan plc
11.6.12 Alimera Sciences Inc.
11.6.13 Phio Pharmaceuticals Corp
11.6.14 Iveric Bio
11.6.15 Belite Bio Inc.
11.6.16 Ocumension Therapeutics Co. Ltd
11.6.17 Eyestem Research Pvt Ltd
11.6.18 Kubota Vision Inc.
12. Analyst Recommendations
12.1 SNS Insider Opportunity Map
12.2 Industry Low-Hanging Fruit Assessment
12.3 Market Entry & Growth Strategy
12.4 Analyst Viewpoint & Suggestions On Market Growth
13. Assumptions
14. Disclaimer
15. Appendix
15.1 List Of Tables
15.2 List Of Figures
